TenNor Clinical Trials

TenNor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of differentiated products for the treatment of unmet medical needs in the areas of infectious diseases and the microbiome. The company utilizes a proprietary Multitargeting Drug Discovery (MTDD) platform to develop dual-acting small molecules that address the challenge of antibiotic resistance. Its lead assets include TNP-2198, currently in Phase 3 for Helicobacter pylori infection, and TNP-2092, which is being evaluated in various formulations for prosthetic joint infections, hepatic encephalopathy, and skin infections. TenNor is headquartered in Suzhou, China, and has established a robust pipeline targeting gastrointestinal and systemic bacterial infections. The company's innovative approach involves conjugating two different antibiotic pharmacophores into a single molecule to enhance efficacy and reduce resistance. TenNor has successfully raised significant capital from leading venture firms to advance its late-stage clinical programs toward commercialization.